Who
Mark Mortenson
Chief Science Officer
Company insider
Files Form 4 as: Chief Science Officer, Clene.
In numbers
- Trades disclosed
- 21
- Buys
- 1
- Sells
- 1
- Bought
- $97K
- Sold
- $50K
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 30 Apr 2021
- Last trade
- 11 Jun 2026
- Last filed
- 15 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 11 Jun 2026filed 15 Jun 2026 | CLNN Cleneoption or derivative · Biotechnology | SEC FORM 4 Code A | —45,000 at $0.00 | filing |
| 11 Jun 2026filed 15 Jun 2026 | CLNN Cleneoption or derivative · Biotechnology | SEC FORM 4 Code A | —45,000 at $0.00 | filing |
| 22 Jan 2026filed 23 Jan 2026 | CLNN Cleneoption or derivative · Biotechnology | SEC FORM 4 Code A | —75,000 at $0.00 | filing |
| 22 Jan 2026filed 23 Jan 2026 | CLNN Cleneoption or derivative · Biotechnology | SEC FORM 4 Code A | —75,000 at $0.00 | filing |
| 25 Sep 2025filed 30 Sep 2025 | CLNN Cleneoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 25 Sep 2025filed 29 Sep 2025 | CLNN Cleneoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 18 Sep 2025filed 19 Sep 2025 | CLNN Cleneoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 24 Feb 2025filed 25 Feb 2025 | CLNN Cleneoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 30 Sep 2024filed 1 Oct 2024 | CLNN Cleneoption or derivative · Biotechnology | SEC FORM 4 Code A | $2,66720,512 at $0.13 | filing |
| 30 Sep 2024filed 1 Oct 2024 | CLNN CleneBiotechnology | SEC FORM 4 Bought | $97K20,512 at $4.75 | filing |
| 16 Aug 2024filed 19 Aug 2024 | CLNN Cleneoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 7 Jun 2024filed 10 Jun 2024 | CLNN Cleneoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,000,000 at $0.00 | filing |
| 7 Jun 2024filed 10 Jun 2024 | CLNN Cleneoption or derivative · Biotechnology | SEC FORM 4 Code A | —800,000 at $0.00 | filing |
| 29 Jun 2023filed 3 Jul 2023 | CLNN Cleneoption or derivative · Biotechnology | SEC FORM 4 Code A | —800,000 at $0.00 | filing |
| 17 Feb 2023filed 21 Feb 2023 | CLNN Cleneoption or derivative · Biotechnology | SEC FORM 4 Code A | —75,000 at $0.00 | filing |
| 4 Nov 2022filed 7 Nov 2022 | CLNN Cleneoption or derivative · Biotechnology | SEC FORM 4 Code A | —400,000 at $0.00 | filing |
| 16 Jun 2022filed 17 Jun 2022 | CLNN CleneBiotechnology | SEC FORM 4 Sold | $50K20,247 at $2.47 | filing |
| 15 Feb 2022filed 16 Feb 2022 | CLNN Cleneoption or derivative · Biotechnology | SEC FORM 4 Code A | —200,000 at $0.00 | filing |
| 4 Nov 2021filed 5 Nov 2021 | CLNN Cleneoption or derivative · Biotechnology | SEC FORM 4 Code A | —200,000 at $0.00 | filing |
| 30 Jun 2021filed 1 Jul 2021 | CLNN CleneBiotechnology | SEC FORM 4 Code A | —50,082 at $0.00 | filing |
News
Clene Announces New Drug Application Submission to FDA for CNM-Au8 for the Treatment of ALSCLNN · manilatimes.net · 19 Oct 2026Head to Head Survey: Shineco (NASDAQ:SISI) vs. Clene (NASDAQ:CLNN)CLNN · tickerreport.com · 8 Oct 2026
0 headlines in the last 90 days name Mark Mortenson; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.